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Edited by Robert B. RussellAbstract A computational approach to predict structures of
rhodopsin-like G protein-coupled receptors (GPCRs) is pre-
sented and evaluated by comparison to the X-ray structural mod-
els. By combining sequence alignment, the rhodopsin crystal
structure, and point mutation data on the b2 adrenoreceptor
(b2ar), we predict a ()-epinephrine-bound computational model
of the b2 adrenoreceptor. The model is evaluated by molecular
dynamics simulations and by comparison with the recent X-ray
structures of b2ar. The overall correspondence between the pre-
dicted and the X-ray structural model is high. Especially the pre-
diction of the ligand binding site is accurate. This shows that the
proposed dynamic homology modelling approach can be used to
create reasonable models for the understanding of structure and
dynamics of other rhodopsin-like GPCRs.
 2008 Published by Elsevier B.V. on behalf of the Federation of
European Biochemical Societies.
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GPCRs form the largest group of membrane receptors and
share a common structural motif of seven transmembrane a-
helices (7TM domain) [1]. Members of this protein family
are the target of more than 50% of drugs sold worldwide [2].
Milestones in understanding of their molecular reaction mech-
anisms are the determinations of the X-ray structures for two
GPCRs: the visual receptor rhodopsin [3,4], and very recently
the b2 adrenoreceptor (b2ar) [5,6]. The rhodopsin structures
stimulated theoretical studies in which it was used as the major
template to explore structural features and mechanisms of
class A receptors [1,7–10], including b2ar [11–14] and other
GPCRs. Our goal here is to set up computational models of
class A GPCRs via homology modelling. They should provide
insight into their structure and dynamic properties in biologi-
cal membranes via unrestrained (free) molecular dynamics
(MD) simulations. So far, this goal has been approached in
various ways [15–19], but due to the lack of information on
a second GPCR structure, the accuracy of the structure predic-
tion was unable to be assessed. The recent publication of the
ﬁrst b2ar crystal structure now allows us to evaluate such
GPCR modelling procedures.*Corresponding author. Fax: +49 234 3214626.
E-mail address: gerwert@bph.rub.de (K. Gerwert).
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doi:10.1016/j.febslet.2008.08.022In the presented approach we combine binary and multiple
sequence alignment, structural features of rhodopsin and point
mutation data on ()-epinephrine-b2ar interaction [20] to cre-
ate a homology model, called B2AR, which is subjected to free
MD simulations in an explicit membrane/solvent environment.
In contrast to docking of ligands into static homology models
[11–14] or static models from frames out of MD simulations
[16–19], B2AR contains an epinephrine molecule in our ap-
proach during the whole simulation period. In so doing we
want to evaluate the quality of possible binding modes pro-
posed by experimental data [20]. We then evaluate structural,
functional and epinephrine binding features of the dynamic
model by comparison with the human b2ar crystal structures.
As the two structures available are rather similar, we focus on
the comparison with the PDB structure 2RH1 [6], which is the
one with the highest resolution.2. Materials and methods
2.1. Sequence alignment
Rat b2ar (UniProtKB accession number P10608) was subjected to
binary alignment with bovine rhodopsin (P02699) using BLAST (BLO-
SUM62 matrix) [21]. For the additional multiple sequence comparison
with ClustalW [22], the class A GPCR sequences P34971, P30546,
P08911, and Q9H205 were included in the alignment. The binary align-
ment was used as the basis for modelling. The multiple alignment was
used to cross-check if motives found to be conserved in the binary align-
ment could be regarded as being modular. Sequence parts with the same
results in both alignments and containing the highest conserved helical
residues [23] were deﬁned as ‘‘anchor groups’’. Gaps within helical re-
gions were moved to loop regions by shifting the sequence towards
the next anchor group. Furthermore intraprotein hydrogen bonds
and salt bridges, and the positioning of positive charges (Arg, Lys,
His) at the level of phosphate groups within the membrane were taken
into consideration as structural restraints. Hydrophilic residues within
the heptahelical transmembrane domain were placed at positions in
which they were oriented towards the protein core. The sequence of
extracellular loop 2 (el2) was shifted to allow the formation of a disul-
phide bond between Cys106 (helix III) and Cys184 (el2), as seen in the
rhodopsin crystal structures. Due to their structural importance for the
C-terminal end of helix VI and the el2, substitution of Trp175 and
Arg177 by analogous residues Trp173 and Arg175 was ensured. As
small ligand binding and structural changes during activation take
place within the 7TM domain [24–26], N-/C-terminal domains and
intracellular loop 3 (il3) were left out for modelling.2.2. Homology modelling
Chain A of rhodopsin crystal structure 1U19 [4] was used as a basis
structure. Internal water molecules were ignored during model build-
ing. As palmityl residues at the end of helix VIII are located on the
protein surface, forming the protein dimerisation interface [6], andation of European Biochemical Societies.
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translational modiﬁcations were not taken into account for modelling.
Sequence replacement was performed with SCWRL [28]. Remaining
sterical clashes were removed with MOBY [29]. Sequence gaps/inserts
in the loop regions were resolved by addition/removal of amino acids,
followed by short periods of simulated annealing (5 ps), energy mini-
misation of the respective loops and full model minimisation.
2.3. Addition of epinephrine
The minimal energy structure and atomic charges of epinephrine
were determined by GAUSSIAN03 [30] vacuum DFT calculations
with B3LYP/6-31++G(d,p) and RESP atomic charges calculation
[31]. The protein model was checked for internal cavities with MOBY.
Epinephrine in its vacuum minimal energy structure was placed into
the only cavity large enough to contain the ligand according to hydro-
gen bond contacts determined in point mutation analysis [20]. These
contacts were: Asp113/ammonium moiety; Asn293/b hydroxyl group;
Ser203, Ser204/meta hydroxyl group; and Ser207/para hydroxyl group.
Epinephrine was subjected to a molecular mechanics steepest descent
minimisation with distance restraints on polar residues in protein side
chains and ligand mentioned above, followed by minimisation of the
ligand plus surrounding residues within 4 A˚. The resulting protein/li-
gand model was used in the following MD simulations.
2.4. Molecular mechanics simulations and data analysis
Simulations were carried out with GROMACS 3.3 [32] by merging
the GROMOS96 force ﬁeld and lipid parameters of Berger et al.
[33,34] according to Schlegel et al. [9]. All acidic/basic side chains were
fully charged except Asp79, which is protonated in rhodopsin [35]. A
topology for ()-epinephrine was obtained from the PRODRG server
[36] with the atomic charges mentioned above. The protein/ligand
model was introduced into an equilibrated bilayer of 256 POPC mol-
ecules, surrounded by a 154 mM NaCl solution, following the proce-
dure of Kandt et al. [37]. The resulting system contains 68770
atoms. After system equilibration, trajectories with a length of 10 ns
were recorded. An analysis of the trajectories (energies, root mean
square displacement (RMSD) and ﬂuctuations (RMSF) of atom coor-
dinates) was performed using GROMACS [29] and MOBY [32] anal-
ysis tools. The root mean square (RMS) deviation of the crystal
structure 2RH1 was calculated from the B factors given in the crystal
structure ﬁle by
ri ¼
ﬃﬃﬃﬃﬃﬃﬃ
Bi
8p2
rFig. 1. Root mean square displacement (RMSD) of the modelled B2AR s
simulation compared to the respective root mean square (RMS) deviation o
root mean square ﬂuctuation (RMSF) of the respective B2AR model atom
simulation, is shown as blue error bars. Positions of the helices highlighted in
resembles the crystal structure.with r being the root mean square deviation of the position of atom i,
and B the respective B factor.3. Results
3.1. Equilibration of model structure
Analysis by MOBY conﬁrmed that the total system energy
(Etot) dropped to its ﬁnal value during unrestrained MD sim-
ulation after 6 ns. The total energy of the protein (Eprot)
reached a minimum after 8 ns. The seven transmembrane heli-
ces remained within an Ca atom RMSD of 2.3 A˚ from the
starting structure. In comparison to 2RH1, it rose to an aver-
age value of 2.5 A˚ within 1 ns, and climbed only slightly to an
average value of 2.8 A˚ after 7 ns. Because of the Ca-RMSD
comparison with 2RH1, we took the last 3 ns of the trajectory
into account for further analysis. During this period, the loop
regions showed pronounced movements with a resulting root
mean square ﬂuctuation (RMSF) of Ca atom coordinates of
1.2–2.0 A˚, while the transmembrane helices remained stable
in position (RMSF of 0.5–0.8 A˚).
3.2. Comparison of X-ray and model structure
In Fig. 1 the X-ray structure and the mean 3-D structure of
our B2AR model during the last 3 ns of MD simulation are
compared with each other. The RMSD resolved for each Ca
atom of the modelled structure is shown. A high correspon-
dence is found for the positions of the seven transmembrane
helices (I-VII). One hundred and thirty eight of 198 (70%) Ca
atoms of the transmembrane helices are within 2.0 A˚ of the
crystal structure. Thereof 75 (38%) are within the RMS devia-
tion calculated from the B factors of atom coordinates in the
crystal structure and thus within the statistical signiﬁcance of
the 2RH1 coordinates (error bar of the B2AR model in
Fig. 1 contains the RMS deviation curve of the b2ar crystal
structural model). They are mostly located in the middle of
the helical bundle. Furthermore, the additional helix VIIItructure from 2RH1 for each Ca atom (red) during last 3 ns of MD
f 2RH1 calculated from B factors of the crystal structure (black). The
coordinates, equalling the RMS deviation of the coordinates during
grey. Letters A–F refer to sites shown in Fig. 2. The 7TM motif closely
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structural model.
As can be seen in Fig. 2A, the remaining 30% of the helices
where there was no match between the model and the X-ray
structure mostly correspond to protein parts with interprotein
contacts, which artiﬁcially stabilise the protein in the crystal.
Such positions (denoted A–F in Figs. 1 and 2) cluster at the
extracellular ends of helices I (A) and VI (E), and the intracel-
lular ends of I (B), III (C), and VII (F). While contacts B and F
connect two proteins in the proposed b2ar dimer [6], A is
formed between two b2ar proteins not engaged in a dimer. C
and E are formed between b2ar and neighbouring T4 lysozyme
portions of the fusion protein. For a more detailed comparison
of the tertiary structure of the two adrenergic receptor models,
their 3-D structures are superposed in Fig. 2B–D. In compar-
ison with the crystal structure, helix I shows a tilt of 33 at the
extracellular and 13 at the intracellular half, with Ile43 being
the centre of rotation, leading to a positional deviation of 10 A˚
of the extracellular and 5 A˚ of the intracellular end. Further
shifts in positions away from their corresponding 2RH1 posi-
tions can be observed for the extracellular ends of II (5 A˚ out-
ward movement), III (4 A˚ inward movement), VI (4 A˚ inward
movement) and VII (4 A˚ outward movement) and the intracel-
lular ends of III (4 A˚ inward movement) and VII (5 A˚ outward
movement). The tilting movement of helix I is followed by a
shift of the extracellular end of II and the intracellular end
of helix VII, leading to their deviation from the crystal struc-
ture. Although the il3 is missing, the intracellular ends of heli-
ces V and VI remain within 4 A˚ of and therefore close to
2RH1.Fig. 2. (A) Interprotein contacts in the crystal structural model. Peak positi
7TM motif. (B–D) Comparison of b2ar crystal structure and mean model stru
intracellular (D) view. 2RH1 in blue, mean structure of the dynamic modelAs expected, larger deviations are observed for the loop re-
gions (extracellular loops (el) 1–3 and intracellular loops (il) 1–
3), but remain reasonably close to the crystal structure. One
exception is el2, which is displaced by up to 20 A˚ (peak D in
Fig. 1). As we start with rhodopsin as the basis structural
information, the loop is present as a b hairpin which enters
deep into the protein core. As a result, the disulphide bond ob-
served in rhodopsin between el2 and helix III is reproduced in
the model by connecting Cys106 (helix III) and Cys184 (el2).
However, crystal structure [6] and point mutation analysis of
b2ar [38] point to two disulphide bonds, one between
Cys106/Cys191, and the other between Cys184/Cys190. Be-
cause the disulphide bonds are not correctly recognized in
the model, the el2 seems thus incorrectly predicted, which
causes the largest deviation between model and X-ray struc-
ture. In 2RH1, the el2 forms a helix on top of the binding cre-
vice instead of the b hairpin deep inside the rhodopsin
molecule. However, the el2 forms various contacts to the T4
lysozyme portion of neighbouring proteins within 2RH1 (con-
tact D in Fig. 2), and thus may not reveal its native structure in
the crystal structure. In addition, the loop is not observed in
the second crystal structure available [5] because of local disor-
der. Due to its disulphide link to the el2, the modelled extracel-
lular top of helix III shows a shift in position relative to 2RH1
as well.
3.3. Dynamic features
In Fig. 3 features of the modelled structure, which are eluci-
dated by dynamics, are shown in detail. Themodel exhibits a sta-
ble interhelical hydrogen bond between the highly conservedons A–F in Fig. 1 coincide with crystal contacts in 2RH1 close to the
cture during last 3 ns of MD simulation: side (B), extracellular (C) and
in green.
Fig. 3. (A) Interhelical contact between Asn51 and Ser319 during free MD simulation. Right: Distance of hydrogen bond donor/acceptor atoms.
Hydrogen bond distances highlighted in yellow. The bond remains stable during simulation. (B) Comparison of ionic lock motifs. Top left: rhodopsin
crystal structure 1U19. Top right: b2ar crystal structure 2RH1. Bottom left: Model after 1.5 ns MD simulation. Bottom right: Distance plot of
Arg131 and Glu268 during free MD simulation. After 0.5 ns, the Glu/Arg ion pair loses its connection.
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This bond creates a stable hydrophilic connection between heli-
ces I and VII. The ionic lock, involving the highly conserved E/
DRY motif in helix III [5], opens during free MD simulation in
nice agreement with the X-ray structure (Fig. 3B): after 0.5 ns,
Arg131 (helix III) loses its connection to Glu268 (helix VI) be-
cause of electrostatic interaction with Asp130.
3.4. Ligand binding site
The ligand binding site in the X-ray and the simulated model
is shown in Fig. 4. The B2AR model shows only one cavitywithin the protein large enough to accommodate the native li-
gand epinephrine. Residues known to be involved in ligand
binding [20] are found at the surface of the cavity. Its location
and form ﬁt well the demands of epinephrine, and is compara-
ble to the one in 2RH1. Deviations in its form are due to a dif-
ferent boundary formed by el2 in our model and the crystal
structure, respectively: while in the crystal structural model
2RH1, the niche is open to the extracellular medium, it is
closed completely by the loop in the simulated model. How-
ever there is a high correspondence in the positions of the li-
gands. The small diﬀerences observed may also be related to
Fig. 4. Protein surface of the binding pocket of B2AR in perpendicular view. Top: crystal structure 2RH1. Carazolol shown in sticks. Bottom:
dynamic model after 10 ns. Epinephrine shown in sticks. The binding pocket in the model is comparable by location and form to the one in 2RH1.
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nephrine used in the model is an agonist, carazolol in the crys-
tal structural model is a partial inverse agonist, which might
bind in a slightly diﬀerent mode. We therefore focus on a de-
tailed evaluation of the binding mode of epinephrine observed
in our B2AR model. Note that docking of the agonist isopro-
teronol into 2RH1 [26] did not result in a reasonable binding
mode, so 2RH1 might be a less suited target for analysis of
agonist binding in b2ar.Fig. 5 shows the contact pattern between epinephrine and
B2AR during free MD simulation and a representative binding
structure after 10 ns of simulation. Epinephrine forms hydro-
phobic contacts to Val114, Phe289, and Phe290, and hydrogen
bonds to Asp113, Asn293, Ser203, Ser204, and Ser207. All res-
idues are known from point mutation analysis and are pro-
posed to interact with epinephrine [20,39,40]. Concerning the
predicted dynamics of those contacts: epinephrine loses its ini-
tial contacts to Ser207 and Asn293 during the ﬁrst 0.1 ns. After
Fig. 5. Ligand binding in dynamic homology model. Left: Contact analysis of receptor model and epinephrine. A: alkyl group or acceptor contact;
B: protein backbone contact; D: donor contact; E: contact on edge of ring; H: hetero group (epinephrine); R: contact on ring plane; S: amino acid
side chain. Epinephrine ammonium moiety and b hydroxyl group contacts remain stable during simulation. The terminal methyl moiety is
intercalated between Phe289 and Phe290. After 5 ns, the catechol ring forms contacts to Val114 and Phe290. The catechol hydroxyl group bond
pattern changes after 5 ns. Right: representative binding mode of epinephrine at 10 ns of free MD simulation. Epinephrine in orange. Epinephrine
forms hydrophobic contacts to Val114, Phe290, and Phe290, and hydrophilic contacts to Asp113, Asn293, Ser203, Ser204, and Ser207.
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it is sandwiched between Val114 and Phe290. The terminal
methyl moiety forms a stable van der Waals contact with the
phenyl rings of Phe289 and Phe290. Unlike in the starting
structure, Asn293 forms a hydrogen bond to the ammonium
moiety instead of the b hydroxyl group of epinephrine, which
engages in a hydrogen bond with Asp113, attaching the ligand
in a clamp-like manner to the carboxylic residue. Ser203 and
Ser207 form hydrogen bond contacts to the meta and para hy-
droxyl groups of epinephrine, respectively, while Ser204 binds
occasionally to the meta hydroxyl group.4. Discussion
While developing our modelling technique before the publi-
cation of the b2ar crystal structures, we appreciate the nice
agreement between our model and the crystal structure during
simulation (see Figs. 1 and 2). The dynamic model is particu-
larly accurate at reproducing the 7TM domains, and the ligand
binding site. The ﬂexible loops show larger deviations, and el2,
which shows the largest deviation between rhodopsin and
b2ar, together with the intramolecular disulphide bond pattern
is not well predicted. However, the deviations between the
modelled and the X-ray structure are mostly related to inter-
protein contacts observed in the crystal.
With respect to dynamic properties, a more detailed compar-
ison shows that the contact of Asn51 and Ser319 connecting
helices I and VII is continuously maintained. This contact
can also be observed in the crystal structural model [6]. It
was already reported to be stable in MD simulations on rho-
dopsin and is believed to be an important and conserved con-
nection motif of GPCRs [9]. Asn51 is the most conserved
residue in Helix I [23]. Point mutation studies on the analogous
a1B-adrenergic receptor [41] demonstrated that a mutation toAla results in a constitutively active receptor, while mutation
to Asp, which can exhibit the observed hydrogen bond as well,
did not have an impact on the receptor function. The hydrogen
bond therefore seems to be important for diﬀerentiating be-
tween active and inactive conformation of the receptor.
The salt bridge formed between Asp130 and Arg131 is
important for keeping the receptor in an inactive state. It is
ruptured via a protonation of Asp130 upon receptor activa-
tion. Mutation of Asp130 to Asn shows an increase in basal
activity of the receptor [42], and Arg131 is a key residue for
G protein binding [24]. The opening of the salt bridge between
Arg131 and Glu268, a feature found in the X-ray structures of
the b2 adrenergic receptor [5,6] but not in rhodopsin, is accu-
rately predicted in the simulated model. Interestingly, point
mutation analysis shows that mutation of Glu268 to Gln or
Ala results in a constitutively active receptor, which was inter-
preted to be related to an interaction between Asp130/Arg131
and Glu268 [42]. Crystal structures and simulation alike point
to a weakening of this interaction in b2ar compared to rhodop-
sin. It seems to be related to the basal activity of b2ar, while
rhodopsin does not exhibit such activity in the inactive state
[5].
As can be seen in Fig. 4, the ligand binding niche is also well
predicted. The behaviour of ()-epinephrine during simulation
(shown in Fig. 5) is remarkable: although ()-epinephrine was
docked into a model derived from rhodopsin in an inactive
conformation, epinephrine ﬁts well into the cavity appearing
during model building in its lowest-energy conformation.
The reorientation after 5 ns positions the ligand into a binding
mode which agrees well with point mutation analysis and li-
gand binding assays. Epinephrine establishes the proposed
hydrogen bond pattern with Serines 203, 204 and 207 men-
tioned in Ref. [43]. The signiﬁcance of hydrophobic contacts
to Phe289 and Phe290 for agonist binding is conﬁrmed by
point mutation analysis [40]. Val114 is highly conserved in
S. Wolf et al. / FEBS Letters 582 (2008) 3335–3342 3341the adrenergic receptor family, and mutation to Ala leads to a
300-fold loss of agonist aﬃnity compared to a 3-fold loss of
antagonist aﬃnity [39]. The clamp-like connection of ammo-
nium group, b hydroxyl group and Asp113 side chain with
Asn293 bonded to the ammonium group explains point muta-
tion data on Asn293 [44] in a way not yet reported. A switch of
enantiomer would interfere with the connection to both
Asp113 and Asn293. Mutation of Asn293 to leucine and sub-
sequent loss of a connecting hydrogen bond would aﬀect bind-
ing negatively as well. Furthermore, mutation of Asn293 to
Asp would put a negatively charged residue close to Asp113
and perturb the binding pattern necessary for receptor activa-
tion, which oﬀers an explanation to the data in Ref. [45]. A
similar ring-like mode can be seen in 2RH1 between carazolol
and Asp113 (see Fig. 4D in Ref. [26]). Docking of epinephrine
into the protein model therefore leads to a dynamic binding
mode which is in agreement with data on ligand binding dur-
ing free MD simulation.5. Conclusions
During free MD simulation, our dynamic homology model
of B2AR reproduces structural and dynamic properties which
are reported for the X-ray structural model. The model exhib-
its a cavity which meets the sterical and electrostatic demands
of the native agonist epinephrine, which binds to the protein in
a stable binding mode during simulation. Therefore, GPCR
models created this way can be used to gain insight into pro-
tein structure, and receptor/ligand binding dynamics which
are not accessible by static homology models.
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